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ABSTRACT The objective of the present study was to
check the efficacy of progress in the medical care of epileptic
pregnant women on the basis of the reduction of different con-
genital abnormalities (CAs) in their offspring. First, the preva-
lence of medically recorded epilepsy was compared in 95
pregnant women who later had offspring with different CAs
(case group) and 90 pregnant women who later delivered
newborn infants without CA (control group) and matched to
cases in the Hungarian Case-Control Surveillance System of
Congenital Abnormalities, 1980–1996. Second, the rate of dif-
ferent CAs was compared in the offspring of epileptic pregnant
women between 1980 and 1989 and 1990–1996. Cleft lip with or
without cleft palate, cleft palate, cardiovascular CAs, oesoph-
ageal atresia/stenosis, hypospadias and multiple CAs showed a
higher risk in the offspring of pregnant women with epilepsy
treated with different antiepileptic drugs, explained mainly by
polytherapy. There was no higher risk for total CAs after mono-
therapy. There was no significantly lower rate of total CAs in
the offspring of epileptic pregnant women during the second
period of the study. The efficacy of special medical care of
epileptic pregnant women was not shown on the basis of
decrease in the rate of CAs in the offspring of epileptic pregnant
women.
Key Words: antiepileptic drug treatment, congenital abnormality,
epilepsy, pregnancy
INTRODUCTION
Epilepsy is defined as a disorder of the brain function characterized
by the periodic and unpredictable occurrence of seizures and is
classified as primary generalized, or focal/partial with or without
secondary generalization. Primary general seizures can be divided
into absence, myoclonic, atonic, or tonic-clonic (Wyllie 2001).
Epilepsy is one of the most frequently studied maternal diseases
during pregnancy (Tompson et al. 1997; Aminoff 2004). Partly
most epilepsies had early onset, and therefore, occured in 0.3–0.6%
of pregnant women. Partly the higher rate of structural birth defects
(i.e. congenital abnormalities [CAs]) in the children of epileptic
women treated with antiepileptic drugs (AEDs) was recognized
after the first paper on the topic (Janz and Fuchs 1964) by Meadow
(1968) and later confirmed by several studies and completed with
minor anomalies, such as broad and low nasal bridge or nail hypo-
plasia (Shepard and Lemire 2004; Briggs et al. 2005) and func-
tional disturbances (e.g. mental retardation) (Meador et al. 2009).
There was a long debate whether this higher risk associated with
epilepsy itself (genetic predisposition or adverse effect of seizures),
AEDs, other (e.g. lifestyle) factors, or their interaction. However,
Holmes et al. (2001) showed that pregnant women with a history of
epilepsy, but without AED treatment during pregnancy had no
higher risk for CA, though it is worth mentioning that untreated
women are expected to be affected with less severe epilepsy (Fried
et al. 2004).
In the 1980s the preconceptional care of epileptic women was
introduced in Hungary (Czeizel 1999; Ero˝s et al. 1998) and special
prenatal care of epileptic pregnant women was recommended
(Tompson et al. 1997; Aminoff 2004). The aim of the study was
therefore to check the efficacy of this recent progress in the medical
care of epileptic pregnant women on the basis of the reduction of
CA, thus the data in the two periods of the study (i.e. 1980 and 1989
and 1990–1996) were compared in the population-based dataset of
the Hungarian Case-Control Surveillance of Congenital Abnormali-
ties (HCCSCA) (Czeizel et al. 2001).
MATERIALS AND METHODS
Cases affected with CAs were selected from the dataset of the
Hungarian Congenital Abnormality Registry (HCAR), 1980–1996
(Czeizel 1997) for the HCCSCA.
Hungarian Congenital Abnormality Registry
Notification of cases with CA is mandatory for physicians from
birth until the end of first postnatal year to the HCAR. Most cases
are reported by obstetricians and pediatricians. In Hungary, practi-
cally all deliveries take place in inpatient obstetric clinics and the
birth attendants are obstetricians. Pediatricians work in the neonatal
units of inpatient obstetric clinics, or in various inpatient and out-
patient pediatric clinics. Autopsy was mandatory for all infant
deaths and common (about 80%) in stillborn fetuses during the
study period. Pathologists sent a copy of the autopsy report to the
HCAR if defects were identified in stillbirths and infant deaths.
Since 1984, fetal defects diagnosed in prenatal diagnostic centers
with or without termination of pregnancy have also been included
into the HCAR.
CAs were differentiated into three groups: lethal (if defects cause
stillbirths or infant deaths or pregnancies are terminated due to fetal
defect in more than 50% of cases), severe (without medical inter-
vention CAs cause handicap or death) and mild (CAs require
medical intervention but life expectancy is good). Lethal and severe
CAs together constitute major CAs. (Minor anomalies or morpho-
logical variants without serious medical or cosmetic consequences
are excluded from the class of CA.) In addition, two main categories
of cases with CAs were differentiated: isolated (only one organ is
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affected) and multiple (concurrence of two or more CAs in the same
person affecting at least two different organ systems).
The total (birth + fetal) prevalence of cases with CA diagnosed
from the second trimester of pregnancy through the age of one year
was 35 per 1000 informative offspring (live-born infants, stillborn
fetuses and electively terminated malformed fetuses) in the HCAR,
1980–1996 (Czeizel 1997) and about 90% of major CAs was
recorded in the HCAR during the 17 years of the study period
(Czeizel et al. 1993). The proportion of live-born infants, stillborn
fetuses and electively terminated malformed fetuses was 97.1%,
1.1% and 1.8%, respectively,
Selection of cases and control for the HCCSCA
There were three exclusion criteria of CAs from the HCAR for the
dataset of the HCCSCA: (i) cases reported after three months of
birth or pregnancy termination (77% of cases were reported during
the first three-month time window and the rest included mainly mild
CAs); (ii) three mild CAs (congenital dysplasia of hip and inguinal
hernia, large hemangioma); and (iii) CA syndromes caused by
major mutant genes or chromosomal aberrations with preconcep-
tional origin.
Controls were defined as newborn infants without CA and were
selected from the National Birth Registry of the Central Statistical
Office for the HCCSCA. In general, two controls were matched to
every case according to sex, birth week in the year when cases were
born, and district of parents’ residence.
Gestational age was calculated from the first day of the last
menstrual period.
Collection of exposure data and confounders in the HCCSCA
Prospective medically recorded data
Mothers were asked in an explanatory letter to send us the prenatal
maternity logbook and other medical records, particularly discharge
summaries concerning their diseases during the study pregnancy and
their child’s CA. These documents were sent back within one month.
Prenatal care was mandatory for pregnant women in Hungary (if a
pregnant woman did not visit a prenatal care clinic, she did not
receive a maternity grant and leave), thus nearly 100% of pregnant
women visited prenatal care clinics, on an average of seven times
during their pregnancies. The first visit was between the 6th and 12th
gestational weeks. The task of obstetricians was to record all preg-
nancy complications, maternal diseases (e.g. epilepsy) and related
drug prescriptions in the prenatal maternity logbook.
Retrospective self-reported maternal information
A structured questionnaire with a list of medicinal products (drugs
and pregnancy supplements) and diseases, plus a printed informed
consent form were also mailed to the mothers immediately after the
selection of cases and controls. The questionnaire requested infor-
mation on pregnancy complications and maternal diseases, on
medicinal products taken during pregnancy according to gestational
months, and on family history of CAs. To standardize the answers,
mothers were asked to read the enclosed lists of medicinal products
and diseases as a memory aid before they filled in the questionnaire.
The mean SD time elapsed between the birth or pregnancy
termination and the return of the information package (question-
naire, logbook, discharge summary, and informed consent form) in
our prepaid envelope was 3.5 1.2 and 5.2 2.9 months in the
case and control groups, respectively.
Supplementary data collection
Regional nurses were asked to visit all non-respondent case mothers
at home to help them fill in the same questionnaire and evaluate the
available medical records, as well as obtain data regarding smoking
and drinking habits through a cross interview of mothers and their
close relatives living together, and finally the so-called ‘family
consensus’ was recorded. Smoking habit was evaluated on the
number of cigarettes per day while three groups of drinking habit
were differentiated: (i) abstinent or occasional drinkers (less than
one drink per week); (ii) regular drinkers (from one drink per week
to one daily drink); and (iii) hard drinkers (more than one drink per
day). Regional nurses visited only 200 non-respondent and 600
respondent control mothers in two validation studies (Czeizel et al.
2003; Czeizel and Vargha 2004) using the same method as in case
mothers, because the committee on ethics considered this follow-up
to be disturbing to the parents of all healthy children.
Overall, the necessary information was available for 96.3% of
cases (84.4% from reply to the mailing, 11.9% from the nurse visit)
and 83.0% of the controls (81.3% from reply, 1.7% from visit).
Informed consent form was signed by 98% of mothers, and names
and addresses were deleted in the remaining 2%.
Herein 17 years of data of the HCCSCA between 1980 and 1996
are evaluated because the data collection has been changed since
1997 (all mothers are visited by regional nurses), and the recent data
had not been validated at the time of the analysis.
Diagnostic criteria of epilepsy in pregnant women
Hungarian medical doctors follow the international recommenda-
tions at the diagnosis of epilepsy, thus it was based on clinical
symptoms, electroencephalograph (EEC) and other examinations.
In the first step of our analysis we selected all pregnant women with
the diagnosis of epilepsy with or without AEDs. In the second step
we differentiated these pregnant women according to the source of
information: (i) prospectively and medically recorded epilepsy in
the prenatal maternity logbook or in discharge summaries of hos-
pitalized pregnant women; and (ii) epilepsy based on only retro-
spective maternal information. Practically all epileptic pregnant
women were recorded by obstetricians in the prenatal maternity
logbook on the basis of the available medical documents. (Only two
pregnant women reported on their untreated epilepsy without
record in the prenatal maternity logbook; these two women were
excluded from the study.) In general, the type of epilepsy was not
mentioned in the prenatal maternity logbook.
Epilepsy-related AED treatments were evaluated according the
chemical structure of medicinal products.
Among potential confounding factors, maternal age, birth order,
marital and employment status as indicators of socio-economic
status (Puho et al. 2005), other maternal diseases and related drug
treatments, as well as folic acid/multivitamin supplementation
(Kjaer et al. 2008; Czeizel 2009) were considered.
Statistical analysis of data
SAS version 8.02 (SAS Institute, Cary, NC, USA) was used for
statistical analyses. Contingency tables were prepared for the main
study variables. First, the characteristics of pregnant women with
epilepsy were compared with all pregnant women without epilepsy
and c2 test was used for categorical variables, while Student’s
t-test was used for quantitative variables. Second, AEDs, other
maternal diseases and related drug treatments were evaluated by
ordinary logistic regression models and odds ratios (OR) with their
95% confidence intervals (CI) were calculated. Third, we com-
pared the prevalence of epilepsy during the study pregnancy in
specified CA groups including at least three cases with the preva-
lence of epilepsy in their all matched control pairs. Adjusted OR
with 95% CI were evaluated in conditional logistic regression
models for the prevalence of epilepsy. We examined confounding
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variables by comparing the OR for epilepsy in the models with and
without inclusion of the potential confounding variables. Maternal
age (<20 years, 20–29 years, and 30 years or more), birth order
(first delivery or one or more previous deliveries), employment
status, and folic acid use (yes/no) were included in the models as
potential confounders. Finally, the total prevalence of cases with
different isolated CAs and with multiple CAs was compared in
epileptic mothers according to the birth year of cases between
1980 and 1989 and 1990–1996.
RESULTS
The total dataset is presented. Of 22 843 cases, 95 (0.42%), while of
38 151 controls without CA, 90 (0.24 %) had mothers with medi-
cally recorded epilepsy in the prenatal maternity logbook (OR with
95% CI: 1.8, 1.3–2.4).
Table 1 summarizes the characteristics of epileptic mothers of
cases and controls, in addition to non-epileptic mothers as refer-
ence. Epileptic mothers were somewhat younger compared to
non-epileptic mothers. The mean birth order was similar in
control mothers with or without epilepsy, but was lower in epi-
leptic case mothers than in non-epileptic case mothers. The pro-
portion of unmarried epileptic women was larger with a lower
proportion of professional/managerial/skilled worker employment
status.
The use of folic acid was lower in epileptic mothers than in
non-epileptic mothers. In addition, the occurrence of folic acid
supplementation was less frequent in epileptic case mothers than in
epileptic control mothers (OR with 95% CI: 0.7, 0.5–0.9). Supple-
mentation with folic acid-containing multivitamins occurred rarely
in the study groups.
Table 2 summarizes the estimated associations between mater-
nal epilepsy and different CAs in their offspring; in addition these
epileptic pregnant women were differentiated according to
without treatment, with mono- and polytherapy. A higher risk
of cleft lip with or without cleft palate, cleft palate, cardio-
vascular CAs, oesophageal atresia/stenosis (though based on
only three cases) and hypospadias was observed in the children of
epileptic pregnant women. Thus, the total rate of CAs was also
higher.
Only 12 epileptic case mothers were recorded without AED
treatment during the study pregnancy, their offspring were affected
Table 1 Maternal characteristics of case and control mothers with epilepsy and without epilepsy as reference
Variables
Case mothers Control mothers
Without epilepsy With epilepsy Without epilepsy With epilepsy
(N = 22 748) (N = 95) (N = 38 051) (N = 90)
Quantitative No. % No. % No. % No. %
Maternal age (years)
19 or less 2 494 11.0 12 12.6 3 271 8.6 6 6.7
20–29 15 525 68.2 68 71.6 27 531 72.3 71 78.9
30 or more 4 729 20.8 15 15.8 7 259 19.1 13 14.4
Mean SD 25.5 + 5.3 24.6 + 4.6 25.5 + 4.9 24.9 + 4.5
Birth order
1 10 654 46.8 54 56.8 18 156 47.7 53 58.9
2 or more 12 094 53.2 41 43.2 19 905 52.3 37 41.1
Mean SD 1.9 + 1.1 1.6 + 0.8 1.7 + 0.9 1.7 + 1.2
Categorical No. % No. % No. % No. %
Unmarried 1 258 5.5 11 11.6 1 462 3.8 10 11.1
Employment status
Professional 1 972 8.7 5 5.3 4 418 11.6 5 5.6
Managerial 5 078 22.3 19 20.0 10 245 26.9 20 22.2
Skilled worker 6 479 28.5 22 23.2 11 885 31.2 23 25.6
Semiskilled worker 4 178 18.4 19 20.0 6 145 16.1 16 17.8
Unskilled worker 1 766 7.8 10 10.5 2 177 5.7 10 11.1
Housewife 2 398 10.5 8 8.4 2 343 6.2 11 12.2
Other 877 3.9 12 12.6 848 2.2 5 5.6
Pregnancy supplements
Iron 14 688 64.6 54 56.8 26 716 70.2 55 61.1
Calcium 1 799 7.9 4 4.2 3 578 9.4 5 5.6
Folic acid 11 245 49.4 34 35.8 20 731 54.5 44 48.9
Vitamin B6 2 004 8.8 9 9.5 4 076 10.7 10 11.1
Vitamin D 6 084 26.7 17 17.9 10 133 26.6 17 18.9
Multivitamins 1 325 5.8 5 5.3 2 500 6.6 9 10.0
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with three different CAs: five cases with cardiovascular CA (crude
OR with 95% CI: 3.3, 1.2–9.2), three cases with hypospadias, two
cases with poly/syndactyly and one case with anencephaly, thus OR
(with 95% CI) was 1.3 (0.7–3.4) for total CA group.
Of 95 epileptic pregnant women, 41 were treated with one AED
(Table 2), and this monotherapy associated with a higher risk with
oesophageal atresia/stenosis, but this association was based on two
cases. However, it is important to mention that there was no sig-
nificantly higher risk for the total group of CAs and any other CA
group. The offspring of 42 epileptic pregnant women with poly-
therapy had a high risk for cleft lip with or without cleft palate, cleft
palate, cardiovascular CA and multiple CAs, thus the risk was also
higher for total CA group (Table 2).
Table 3 shows the numerical distribution of different CAs
according to AEDs used in monotherapy. Of eight cases with car-
diovascular CA, four had mothers with carbamazepine, while
three were treated with phenytoin. Of seven cases with hypospa-
dias, three had epileptic mothers treated with valproate and two
were treated with phenytoin. Of six cases with undescended testis,
three had epileptic mothers with phenytoin treatment. Of four
cases with neural-tube defect, two had mothers with carbam-
azepine, one with phenytoin and one with valproate treatment.
However, the most impressive finding is the low number of
cleft palate and cleft lip with or without cleft palate after
monotherapy.
The different combinations of AEDs in polytherapy are shown in
Table 4. Most frequently, primidone, phenytoin and carbamazepine
were used, followed by diazepam and sultiame. Phenytoin and
diazepam occurred most frequently in polytherapy in the group of
Table 3 Controls and cases born to mothers with monotherapy, polytherapy and without treatment according to antiepileptic drug
Antiepileptic Control
Monotherapy
Others MCA TotalNTD CLP CP CCM OAT SH UT CF PY/SY
Carbamazepine (Ca) 10 2 0 0 4 0 1 0 2 0 0 0 8
Clomethiazol (Cl) 0 0 0 0 1 1 0 0 0 0 0 0 2
Clonazepam (Cz) 1 0 0 0 0 0 0 0 0 0 0 0 0
Diazepam (Di) 4 0 0 1 0 0 1 0 0 0 0 0 2
Ethosuximide (Et) 0 0 1 0 0 1 0 0 0 0 0 0 2
Mephenytoin (Me) 2 0 0 0 0 0 0 0 0 0 0 0 0
Morsumide (Mo) 2 0 0 0 0 0 0 0 0 0 0 0 0
Phenacemide (Pa) 0 0 0 0 0 0 0 0 0 0 0 0 0
Phenobarbital (Pb) 0 0 0 0 0 0 0 1 0 0 0 0 1
Phenytoin (Pt) 19 1 1 1 3 0 2 3 1 0 2† 0 14
Primidone (Pr) 6 0 0 0 0 0 0 1 1 0 1‡ 1 4
Sultiame (Su) 0 0 0 0 0 0 0 0 0 0 0 0 0
Trimethadione (Tr) 1 0 0 0 0 0 0 0 0 1 0 0 1
Valproate (Va) 5 1 0 0 0 0 3 1 0 0 1§ 0 7
Total 50 4 2 2 8 2 7 6 4 1 4 1 41
Polytherapy 30 2 9 3 12 1 3 1 1 2 4 4 42
No drug treatment 10 1 0 0 5 0 3 0 0 2 1 0 12
Grand total 90 7 11 5 25 3 13 7 5 5 9 5 95
†Exomphalos, atresia of bile duct; ‡Branchial cyst; §Microtia.
CCM, cardiovascular congenital abnormalities (CAs); CF, clubfoot; CLP, cleft lip with or without cleft palate; CP, cleft palate; MCA,
multiple CA; NTD, neural-tube defect; OAT, oesophageal atresia/stenosis; PY/SY, poly/syndactyly; SH, hypospadias; UT, undescended
testis.
Table 4 Antiepileptic drugs used in polytherapy according to
different congenital abnormalities (CAs)
CA group Specified CA = antiepileptic drugs
NTD Spina bifida = 2: Va + Pr, Va + Ca + Pr
CLP Cleft lip = 6: Pt + Di, Pt + Pr, Pt + Ca + Su, Di + Pr,
Di + Ca + Me, Pr + Tr + Su
Cleft lip with cleft palate = 3: Pt + Di, Pt + Pr,
Pt + Ca + Di + Su + Me
CP Cleft palate = 3: Ca + Di, Ca + Tr, Ca + Pr + Pb
CCM Ventricular septal defect = 8: Pt + Di, Pt + Pr + Me,
Di + Su + Pr,
Di + Su + Mo, Ca + Su + Pb, Pr + Su, Pr + Et,
Pr + Me + Pa
Atrial septal defect = 1: Pt + Pr - Di
Unspecified = 3: Pt + Me, Pt + Di + Ca,
Di + Ca + Pr + Et
OAT Oesophageal atresia with oesophageal – tracheal
fistula = 1: Ca + Va + Su
SH Hypospadias = 3: Pt + Di, Va + Di, Va + Di
The abbreviations of different CAs and antiepileptic drugs are
shown in Table 3.
The abbreviations of most frequently used drugs are printed in
italic.
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cleft lip with or without cleft palate. Interestingly, cleft palate
showed a different pattern because carbamazepine was the common
component in the polytherapy of this CA group. The most frequent
components of polytherapy were primidone and phenytoin in the
group of cardiovascular CAs with an obvious dominance of ven-
tricular septal defect. In the group of neural-tube defects valproate
and primidone were components of polytherapy in both cases. In
the group of hypospadias, diazepam and valproate were the leading
components of polytherapy. Some drugs, such as clonazepam,
mephenytoin, morsumide, phenacemide and sultiame were used
only in polytherapy.
The combined effect of different AEDs in mono- and
polytherapy confirmed the well-known teratogenic effect of
valproate, phenytoin and primidone. In addition, our data indi-
cated the teratogenic effect of sultiame (OR with 95% CI: 5.7,
1.6–14.4). However, the risk of CAs did not reach the level of
significance after the use of carbamazepine (OR with 95% CI:
1.9, 0.9–4.3). The number of pregnant women with trimethadione
treatment was too small for evaluation. These Hungarian data did
not confirm the teratogenic potential of phenobarbital (OR with
95% CI: 1.3, 0.6–2.6) and diazepam (OR with 95% CI: 1.1,
0.7–1.7).
In the second step of the study we compared the data of cases
with CAs between 1980 and 1989 and 1990–1996. There was no
significant change in maternal characteristics of epileptic pregnant
women between the two study periods.
Table 5 summarized the data of different CAs in the offspring of
pregnant women without treatment, as well as with mono- and
polytherapy between 1980 and 1989 and 1990–1996. The number
of mono- and polytherapy was 28:31 between 1980 and 1989, while
this ratio was 13:11 between 1990 and 1996 thus the proportion of
polytherapy decreased but it was far from the level of significance
(P = 0.58). In addition, there was a decrease in the total rate of CAs
from 0.44 % to 0.36% (OR with 95% CI: 0.82, 0.56–1.13), that is,
this decline was about 20% due to the decrease in their rate both
after mono- and polytherapy in the second period of the study. It is
worth mentioning the lack of cases with cleft palate in the second
period.
The comparison of different antiepileptic drug uses between the
two study periods (Table 6) shows that the use of carbamazepine
and mainly valproate increased, while the use of phenytoin
decreased in epileptic mothers. On the other hand these data indi-
cate that the reduction of polytherapy occurred mainly in control
mothers.
DISCUSSION
The aim of the study was to check the efficacy of recent progress in
the care of epileptic pregnant women. Our data showed some
increase in the proportion of recommended monotherapy and a 20%
reduction in the risk for total CAs during the second period of the
study. Thus, a real breakthrough in the efficacy of recent medical
care of epileptic pregnant women regarding the teratogenic risk of
AED has not been found.
In the total material, a higher risk for total CAs was found only
after polytherapy, explained mainly by the higher rate of cleft lip
with or without cleft palate, cleft palate, cardiovascular CAs and
multiple CAs. Thus, the lower teratogenic potential of mono-
therapy was confirmed. In addition this study confirmed the ter-
atogenic effect of phenytoin, valproate, primidone and completed
this list with the teratogenic effect of sultiame (Czeizel et al.
1992). However, this Hungarian material did not confirm the
teratogenic effect of carbamazepine, diazepam and pheno-
barbital. The recognition of mild teratogenic potential of carbam-
azepine depends on the number of pregnant women (i.e. statistical
power).
The teratogenic potential of diazepam and phenobarbital
depends on the indication of these drugs (i.e. underlying maternal
diseases). The recent Cochrane review of these drugs has not con-
firmed their teratogenic potential (Adab et al. 2004). A population-
based monitoring system of self-poisoning pregnant women (i.e.
pregnant women who attempted suicide with extremely large
doses of drugs) was established in Budapest (Czeizel et al. 2008).
Among 1044 self-poisoned pregnant women, 112 used very large
doses of diazepam (25–800 mg) and 37 women attempted suicide
between the 4th and 12th gestational weeks, but a higher rate of
CAs was not detected (Gidai et al. 2008). In addition, 88 pregnant
women attempted suicide with very large doses of pheno-
barbital and 34 women between the 4th and 12th gestational
weeks, but a higher risk of CAs was not found (Timmemann et al.
2009).
The strengths of the HCCSCA are that is a population-based
large dataset including 185 pregnant women with prospectively
and medically recorded epilepsy in an ethnically homogeneous
European (Caucasian) population. We were able to differentiate
the different groups of AEDs in the study pregnancies. Additional
strengths are the matching of cases to controls without CA;
available data for potential confounders, and finally that the diag-
nosis of medically reported CAs was checked in the HCAR
(Czeizel 1997) and later modified, if necessary, on the basis of
recent medical examination within the HCCSCA (Czeizel et al.
2001).
However, this dataset also has limitations: (i) We did not know
any details regarding the onset of epilepsy before the study preg-
nancy; (ii) Other pregnancy outcomes (e.g. miscarriages) were not
known; (iii) Unfortunately, our dataset is not appropriate for the
evaluation of functional defects (e.g. valproate associates with the
most severe mental retardation-inducing effect); (iv) In general,
the doses of AEDs drugs used for the treatment of epileptic preg-
nant women were not known, but the results of our validation
studies showed that recommended doses were used in most preg-
nant women (Czeizel et al. 2003); (v) The data of blood level of
AEDs were not recorded in the HCCSCA; and (vi) The major
weakness of our study is that the recent data of pregnant women
(i.e. after 1996) are not available in the HCCSCA.
The major message of this study and some other recent papers is
that pregnancy in epileptic women does not need to be discouraged
if these women wish to have babies, but epileptic women need a
specific and high standard of medical care.
The first task is to educate epileptic women to understand that
it is necessary to prepare their pregnancies before conception.
There are many tasks during this preconceptional period: (i)
Check their AEDs and attempt changing the teratogenic drugs
(e.g. valproate) to less (e.g. carbamazepine) or non-teratogenic
(lamotrigine) drugs under control of specialists. However, at the
selection of AEDs for epileptic pregnant women the type of epi-
lepsy is the most important aspect, but some other aspects (e.g.
the duration previous seizure-free interval, other diseases) can also
be considered; (ii) In general, monotherapy is better because poly-
therapy associates with a higher risk of CAs (Källen 1986,
Meador et al. 2008) as in our study; (iii) The use of the lowest
effective dose of the given drug is preferable, because higher
doses of AEDs associate with a higher risk of specific CAs; (iv)
However, it is important to stress that the cluster of seizures
during pregnancy in untreated or inappropriately treated epileptic
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women associates with an even higher risk of fetal defects
(Meador et al. 2008). Thus, epileptic pregnant women need treat-
ment during pregnancy as well.
The second task is the monitoring of health status of epileptic
pregnant women and their fetuses. The relation of epilepsy and
pregnancy is variable, about 45% of pregnant women have a higher
seizure frequency, while about 5% associate with a reduced seizure
frequency, thus epilepsy remains unchanged in about 50% of preg-
nant women (Knight and Rhind 1975). The higher risk for seizure is
explained by generally declined serum levels of AEDs in preg-
nancy, therefore an increase in dosage is frequently required during
pregnancy to maintain the effective plasma level of AEDs
(Tompson et al. 1997). Another task is the monitoring of the fetal
development with high-resolution ultrasound because the principal
defects associated with different teratogenic AEDs, such as neural-
tube defects (Meador et al. 2008) and fetal hydantoin/dilantin/
phenytoin, fetal trimethadione and fetal valproate syndrome/effect
(Jones 1988) are detectable approximately at the 20th gestational
week. These defects are rarely diagnosed, but pregnant women have
the right to decide to keep or terminate their pregnancies after their
diagnosis.
The final task is connected with the preparation of delivery,
including maternal ingestion of vitamin K1 (10 mg per day)
because clinical or subclinical coagulopathy may occur in newborn
infants (Aminoff 2004).
In conclusion, the main experience of this study is that the above
principles have not been followed in many Hungarian
pregnant women, therefore, the efficacy of recent special medical
care of epileptic mothers was not obvious in the reduction of CAs.
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